Ipragliflozin

ALIMENTARY TRACT AND METABOLISM

Key facts

Ipragliflozin is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2014. DrugCentral lists 6 molecular targets, including Slc5a2, Slc5a2 and SLC5A2. Recorded indications include Diabetes mellitus type 1 and Diabetes mellitus type 2.

• Molecular targets: Slc5a2, Slc5a2, SLC5A2 and Slc5a1 (6 listed in DrugCentral).
• Indications: Diabetes mellitus type 1 and Diabetes mellitus type 2.
• ATC code: A10BK05 (Sodium-glucose co-transporter 2 (SGLT2) inhibitors).
• Molecular formula: C21H21FO5S; molecular weight 404.45 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Diabetes mellitus type 1
• Diabetes mellitus type 2

Mechanism & targets

Molecular targets (6)

Target	Gene	Action	Activity
Sodium/glucose cotransporter 2	Slc5a2	inhibitor	IC50 8.25
Sodium/glucose cotransporter 2	Slc5a2	inhibitor	IC50 8.20
Sodium/glucose cotransporter 2	SLC5A2	inhibitor	IC50 8.13
Sodium/glucose cotransporter 1	Slc5a1	inhibitor	IC50 5.93
Sodium/glucose cotransporter 1	Slc5a1	inhibitor	IC50 5.86
Sodium/glucose cotransporter 1	SLC5A1	unknown	IC50 5.73

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2014-01-17	PMDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
A10BK05	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Diabetic ketoacidosis	69.1
Cerebral infarction	60.2
Diabetes mellitus inadequate control	56.5
Hypoglycaemia	45.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ipragliflozin is on its molecule page.

• Molecular formula: C₂₁H₂₁FO₅S
• Molecular weight: 404.45 g/mol
• CAS number: 761423-87-4
• InChIKey: AHFWIQIYAXSLBA-RQXATKFSSA-N
• PubChem CID: 10453870

OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC3=C(S2)C=CC=C3)=C(F)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ipragliflozin used for?

DrugCentral lists the following indications for Ipragliflozin: Diabetes mellitus type 1 and Diabetes mellitus type 2.

How does Ipragliflozin work?

Its molecular targets in DrugCentral include Slc5a2 (inhibitor), Slc5a2 (inhibitor), SLC5A2 (inhibitor) and Slc5a1 (inhibitor).

When was Ipragliflozin first approved?

Ipragliflozin was first approved by the PMDA in 2014.

What is the chemical formula of Ipragliflozin?

Ipragliflozin has the molecular formula C21H21FO5S and a molecular weight of 404.45 g/mol.

Sources

• DrugCentral drug card 4890 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2018096 — compound record and bioactivity
• PubChem CID 10453870 — chemical identifiers
• DrugBank DB11698 — drug record
• FDA UNII 3N2N8OOR7X — substance identity
• UniProt P31639 (SLC5A2) — target protein
• UniProt P13866 (SLC5A1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.